<sup>18</sup>F-AlF-NOTA-Octreotide Outperforms<sup>68</sup>Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study

Elin Pauwels(KU Leuven), Christophe M. Deroose(KU Leuven), Karen Geboes(Universitair Ziekenhuis Leuven), Willem Lybaert, Bliede Van den Broeck(Ghent University Hospital), Frederik Cleeren(KU Leuven), Sigrid Stroobants(University of Antwerp), Térence Tshibangu(KU Leuven), Annouschka Laenen(Statistics Belgium), Timon Vandamme(University of Antwerp), Michel Koole(KU Leuven), Lennert Boeckxstaens(KU Leuven), Kim Serdons(KU Leuven), Jeroen Dekervel(Universitair Ziekenhuis Leuven), Guy Bormans(KU Leuven), Chris Verslype(Universitair Ziekenhuis Leuven), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven)
Journal of Nuclear Medicine
October 20, 2022
10.2967/jnumed.122.264563
Cited by 74

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k